Pibrentasvir

Pibrentasvir
Clinical data
Trade names	Mavyret, Maviret (combination with glecaprevir)
Synonyms	ABT-530
Pharmacokinetic data
Protein binding	>99.9%
Elimination half-life	13 hours
Excretion	96.6% in faeces
Identifiers
	IUPAC name Methyl {(2S,3R)-1-[(2S)-2-{5-[(2R,5R)-1-{3,5-difluoro-4-[4-(4-fluorophenyl)-1-piperidinyl]phenyl}-5-(6-fluoro-2-{(2S)-1-[N-(methoxycarbonyl)-O-methyl-L-threonyl]-2-pyrrolidinyl}-1H-benzimidazol-5-yl)-2-pyrrolidinyl]-6-fluoro-1H-benzimidazol-2-yl}-1-pyrrolidinyl]-3-methoxy-1-oxo-2-butanyl}carbamate;
CAS Number	1353900-92-1;
PubChem CID	58031952;
ChemSpider	35013016;
UNII	2WU922TK3L;
KEGG	D10816;
Chemical and physical data
Formula	C57H65F5N10O8
Molar mass	1,113.20 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@H]([C@@H](C(=O)N1CCC[C@H]1c2[nH]c3cc(c(cc3n2)[C@H]4CC[C@@H](N4c5cc(c(c(c5)F)N6CCC(CC6)c7ccc(cc7)F)F)c8cc9c(cc8F)[nH]c(n9)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)OC)NC(=O)OC)F)NC(=O)OC)OC;
	InChI InChI=1S/C57H65F5N10O8/c1-29(77-3)49(67-56(75)79-5)54(73)70-19-7-9-47(70)52-63-41-25-35(37(59)27-43(41)65-52)45-15-16-46(72(45)34-23-39(61)51(40(62)24-34)69-21-17-32(18-22-69)31-11-13-33(58)14-12-31)36-26-42-44(28-38(36)60)66-53(64-42)48-10-8-20-71(48)55(74)50(30(2)78-4)68-57(76)80-6/h11-14,23-30,32,45-50H,7-10,15-22H2,1-6H3,(H,63,65)(H,64,66)(H,67,75)(H,68,76)/t29-,30-,45-,46-,47+,48+,49+,50+/m1/s1; Key:VJYSBPDEJWLKKJ-NLIMODCCSA-N;

Pibrentasvir is an antiviral agent.^[1] In the United States and Europe, it is approved for use with glecaprevir as the combination drug glecaprevir/pibrentasvir (trade name Mavyret in the US and Maviret in the EU) for the treatment of hepatitis C.^[2]^[3] It is sold by Abbvie.

References

↑ Ng, Teresa I.; Krishnan, Preethi; Pilot-Matias, Tami; Kati, Warren; Schnell, Gretja; Beyer, Jill; Reisch, Thomas; Lu, Liangjun; Dekhtyar, Tatyana; Irvin, Michelle; Tripathi, Rakesh; Maring, Clarence; Randolph, John T.; Wagner, Rolf; Collins, Christine (2017). "In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir". Antimicrobial Agents and Chemotherapy. 61 (5): e02558–16. doi:10.1128/AAC.02558-16. PMID 28193664.
↑ Linda A. Johnson (August 3, 2017). "FDA OKs new drug to treat all forms of hepatitis C". Fox Business.
↑ "Maviret: EPAR – Summary for the public" (PDF). European Medicines Agency. 2017-08-17.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.